



October 3, 2008

Robert Levine MD
ArchieMD
3600 FAU BLVD Suite 201
Boca Raton, FL 33431

Re: Protocol #: ArchieMD: the science of drugs; an educational evaluation
IRB Tracking #: NID1-08-303

Dear Dr. Levine,

As your IRB of record for the above referenced study, the Copernicus Group IRB board has reviewed your submission information. Enclosed is your approval notice. Be sure to carefully maintain the original documents so that copies may be made when necessary. As Principal Investigator, you agree to uphold your responsibility to protect the rights and welfare of your subject at all times while adhering to all applicable federal regulations governing the conduct of clinical research trials.

Copernicus Group IRB reserves the right to visit your research site at any time with appropriate prior notice.


We are also enclosing a Copernicus Group IRB Investigator Guidebook that details the IRB's expectations, procedures and contact information. Please carefully read this Guidebook and have your study staff do the same. CGIRB forms and additional information regarding the conduct of clinical trials are available on our web site: www.cgirb.com.

If you have any questions regarding the contents of this letter or your working relationship with Copernicus Group IRB, please do not hesitate to call us at 1-888-303-2224 or email us at irb@cgirb.com. To avoid delay in locating your records we ask that you refer to the IRB Tracking number located in the header of this letter.

We look forward to working with you.

Copernicus Group IRB

cc: Jill Graygo, ArchieMD, Inc. (Email)



IRB APPROVAL DATED:
October 2, 2008
EXPIRATION DATE: October 1, 2009

Investigator: Robert Levine MD
Approval Includes:
 Protocol
 Post feedback computer users
 ArchieMD Pre-test
 ArchieMD post-test
 Parent Memo
 Principal Investigator
 Waiver of Documentation of Parental Permission and Assent

Investigator Address: Robert Levine MD

ArchieMD
3600 FAU BLVD Suite 201
Boca Raton, FL 33431

Sponsor: National Institute of Drug Abuse

Protocol Title: ArchieMD: the science of drugs; an educational evaluation



Approval is granted subject to the following considerations:

- Responsibilities of the Principal Investigator as found in the Investigator Guidebook
- Please note that if revisions are required for any approved item (particularly advertisements), they must be approved prior to use.

IF YOU HAVE ANY QUESTIONS, CALL COPERNICUS GROUP IRB AT 1-888-303-2224

This signature certifies that the information contained in this IRB Approval Notice is true and correct as verified by the minutes and records of The Copernicus Group, Inc. It also certifies that The Copernicus Group, Inc. is in full compliance with FDA Code of Federal Regulations (21 CFR Parts 50, 56, 312, and 812 and 45 CFR) and ICH Guidelines.

Signature Megan Aiken Date 10/6/08 IRB TRACKING # NID1-08-303
 Authorized Signature

 	CGIRB Indemnification Agreement	Internal Use SEP 25 2008
---	--	---------------------------------

Re: Name of Sponsor/Company: ArchieMD, Inc.
Protocol #:
Study Title: ArchieMD: Science of Drugs Evaluation

~~ADD 1-18-2003~~
 NO FOR-303 *MT*
 9/23/08

1. ArchieMD, Inc. ("Sponsor/Company") agrees to defend, indemnify, and hold harmless The Copernicus Group Inc., its employees, agents, and independent contract personnel, and its independent review board and board members, (collectively referred to as "Copernicus Group IRB"), in connection with Copernicus Group IRB's independent review board review activities from and against any and all losses, liabilities, claims, expenses, and judgments, including without limitation litigation costs and reasonable attorney's fees, which losses, liabilities, claims, expenses, and/or judgments may be incurred or asserted, directly or indirectly, in relationship to or as arising from the Study(ies) noted below:

(i) for all studies sponsored by Sponsor/Company beginning on or after 9-16-08 (the "Studies");
 OR

(ii) for a single protocol and study: Protocol # Study Title (the "Study")

2. However, Sponsor/Company will not indemnify Copernicus Group IRB in connection with losses, liabilities, claims, expenses, and/or judgments which are solely the result of Copernicus Group IRB's negligence or willful misconduct in connection with its independent review board activities as determined by a court.

Sponsor/Company: ArchieMD, Inc.

Robert Levine

Signature

Printed Name

President

9/16/08

Title

Date

The Copernicus Group, Inc.

Dawn Pope
 Director, IRB Services & Study Start Up

Signature

Printed Name

9.29.08

Title

Date